Palvella Therapeutics Inc/$PVLA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Palvella Therapeutics Inc
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
- Ticker
- $PVLA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Wayne, United States
- Website
- palvellatx.com
PVLA Metrics
BasicAdvanced
$1.7B
-
-$4.90
-
-
Price and volume
Market cap
$1.7B
52-week high
$161.38
52-week low
$68.96
Average daily volume
229K
Financial strength
Current ratio
21.179
Quick ratio
21.008
Long term debt to equity
0.103
Total debt to equity
0.104
Interest coverage (TTM)
-7.60%
Profitability
Management effectiveness
Return on assets (TTM)
-22.05%
Return on equity (TTM)
-46.63%
Valuation
Price to book
7.99
Price to tangible book (TTM)
7.99
Price to free cash flow (TTM)
-41.503
Free cash flow yield (TTM)
-2.41%
Free cash flow per share (TTM)
-2.899
Growth
Earnings per share change (TTM)
19.98%
What the Analysts think about PVLA
Analyst ratings (Buy, Hold, Sell) for Palvella Therapeutics Inc stock.
Analyst projections of the future price of Palvella Therapeutics Inc stock.
Bulls say / Bears say
Phase 3 SELVA met its primary, key secondary and all four other efficacy endpoints, each with p<0.001. Among participants aged six and older who completed the 24-week evaluation, 86% were rated much or very much improved. (GlobeNewswire)
Palvella has completed its NDA submission under the 505(b)(2) pathway, and QTORIN has Breakthrough Therapy, Fast Track and Orphan Drug designations. With no FDA-approved treatment for microcystic lymphatic malformations, approval could give the company a first-in-disease product. (GlobeNewswire)
QTORIN also showed a signal in cutaneous venous malformations: in the Phase 2 TOIVA study, patients with bleeding at baseline had a statistically significant improvement in bleeding scores at week 12. This could broaden the product’s opportunity beyond its lead indication if later development confirms the result. (SEC)
The completed NDA is not an approval, and the company’s planned first-half 2027 launch is conditional on FDA approval. A regulatory setback or delay could push out the first product revenue. (GlobeNewswire)
Palvella is still loss-making and depends on its cash to fund development and launch preparation: its first-half 2026 net loss was $37.6 million, up from $17.7 million a year earlier, and operating cash use nearly doubled. Continued spending before commercial revenue raises the risk that it will need more capital if launch or sales are delayed. (StockTitan)
The venous-malformation programme is less advanced: TOIVA was a single-arm, open-label Phase 2 study, and the FDA did not grant breakthrough designation on the initial 12-week data package. It still needs later-stage evidence and regulatory alignment before it can become a second product opportunity. (GlobeNewswire, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
PVLA Financial Performance
Revenues and expenses
PVLA Earnings Performance
Company profitability
Upcoming events
No upcoming events
PVLA News
AllArticlesVideos
Funds containing PVLA
AllEURGBPUSD
Fund name | Fund size | $PVLA weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.05% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.